Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells

Molecular Cancer Therapeutics

Volumn 6, Issue 4, 2007, Pages 1292-1299

  Salido, Mercedes ^a,b   Gonzalez, Juan L ^a   Vilches, Jose ^a  

^a UNIVERSITY OF CÁDIZ   (Spain)

^b Escuela de Ciencias de la Salud   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN; ETOPOSIDE; NEUROPEPTIDE;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; CELL GROWTH; CELL KINETICS; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOCHEMISTRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MODULATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUANTITATIVE ANALYSIS;

ANALYSIS OF VARIANCE; APOPTOSIS; BOMBESIN; CELL LINE, TUMOR; CELL SURVIVAL; CONFIDENCE INTERVALS; ETOPOSIDE; HUMANS; KINETICS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; MITOCHONDRIA; PROSTATIC NEOPLASMS;

EID: 34248233130     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0681     Document Type: Article

References (47)

1. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47:147-55.
2. Quek ML, Daneshmand S, Rodrigo S, et al. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology 2006;67:1247-52.
3. Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco F, Di Silverio F. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract 2006;60:462-70.
4. Slovin SF. Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing? Nat Clin Pract Urol 2006;3:138-44.
5. Wilson EM, Oh Y, Hwa V, Rosenfeld RG. Interaction of IGF-binding protein-related protein 1 with a novel protein, neuroendocrine differentiation factor, results in neuroendocrine differentiation of prostate cancer cells. J Clin Endocrinol Metab 2001;86:4504-11.
6. Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 2005;28:141-5.
7. Cabrespine A, Guy L, Gachon F, Cure H, Chollet P, Bay JO. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. J Urol 2006;175:1347-52.
8. Ranno S, Motta M, Rampello E, Risino C, Bennati E, Malaguarnera M. The chromogranin-A (CgA) in prostate cancer. Arch Gerontol Geriatr 2006;43:117-26.
9. Salido M, Vilches J, Lopez A, Roomans GM. Neuropeptides bombesin and calcitonin inhibit apoptosis related elemental changes in prostate cancer cell lines. Cancer 2002;94:368-77.
10. Antonsson B. Mitochondria and the Bcl-2 family proteins in apoptosis signaling pathways. Mol Cell Biochem 2004;256/257:141-55.
11. 6(3) or rhodamine 123, is a reliable fluorescent probe to asses Δψ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997;411:77-82.
12. Follstad BD, Wang DI, Stephanopoulos G. Mitochondrial membrane potential differentiates cells resistant to apoptosis in hybridoma cultures. Eur J Biochem 2000;267:6534-40.
13. Xu M, Ashraf M. Melatonin protection against lethal myocyte injury induced by doxorubicin as reflected by effects on mitochondrial membrane potential. J Mol Cell Cardiol 2002;34:75-9.
14. Custodio JB, Cardoso CM, Madeira VM, Almeida LM. Mitochondrial permeability transition induced by the anticancer drug etoposide. Toxicol In Vitro 2001;15:265-70.
15. Fuller KM, Arriaga EA. Advances in the analysis of single mitochondria. Curr Opin Biotechnol 2003;14:35-41.
16. Vilches J, Salido M. Mitochondria and cell death. Histol Histopathol 2005; suppl 1: S58-59.
17. Vilches J, Salido M. Neuropeptides as modulators of apoptosis in prostate cancer. In: Figgins HC, editor. Trends in cell apoptosis research. New York: Nova Publishers, Inc., in press 2007.
18. Salido M, Larran J, Lopez A, Vilches J, Aparicio J. Etoposide sensitivity of human prostatic cancer cell lines PC-3, DU 145 and LNCaP. Histol Histopathol 1999;14:125-34.
19. Salido M, Vilches J, Lopez A. Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines. Histol Histopathol 2000;15:729-38.
20. Salido M, Vilches J, López A, Roomans GM. X-ray microanalysis of etoposide induced apoptosis in the PC-3 prostatic cancer cell line. Cell Biol Int 2001;25:499-508.
21. Salido M, Vilches J, Roomans GM. Changes in elemental concentrations in LNCaP cells are associated with a protective effect of neuropeptides on etoposide-induced apoptosis. Cell Biol Int 2004;28: 397-402.
22. Vilches J, Salido M, Fernandez-Segura E, Roomans GM. Neuropeptides, apoptosis and ion changes in prostate cancer. Methods of study and recent developments. Histol Histopathol 2004;19:951-61.
23. Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urology 2006;68:2-8.
24. Yamada Y, Nakamura K, Aoki S, et al. Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome? Oncol Rep 2006;15:1309-13.
25. Theodoropoulos VE, Tsigka A, Mihalopoulou A. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005;66: 897-902.
26. Lawen A. Apoptosis an introduction. Bioessays 2003;25:888-96.
27. Kuznetsov AV, Usson Y, Leverve X, Margreiter R. Subcellular heterogeneity of mitochondrial function and dysfunction: evidence obtained by confocal imaging. Mol Cell Biochem 2004;256-257:359-65.
28. Petronilli V, Penzo D, Scorrano L, Bernardi P, Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J Biol Chem 2001;276:12030-4.
29. Lim ML, Lum MG, Hansen TM, Roucou X, Nagley P. On the release of cytochrome c from mitochondria during cell death signaling. J Biomed Sci 2002;9:488-506.
30. James AM, Murphy MP. How mitochondrial damage affects cell function. J Biomed Sci 2002;9:475-87.
31. Robertson JD, Orrenius S. Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol 2000;30:609-27.
32. Bouchier-Hayes L, Lartigue L, Newmeyer D. Mitochondria: pharmacological manipulation of cell death. J Clin Invest 2005;115:2640-7.
33. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol 2006;147:239-48.
34. Armstrong JS. Mitochondrial membrane permeabilization: the sine qua non for cell death. Bioessays 2006;28:253-60.
35. Mathur A, Hong Y, Kemp BK, Alvarez A, Erusalimsky JD. Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. Cardiovasc Res 2000;46:126-38.
36. Dedov VN, Cox GC, Roufogalis BD. Visualisation of mitochondria in living neurons with single and two-photon fluorescence laser microscopy. Micron 2001;32:653-60.
37. Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G. Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 2002;265:39-47.
38. Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004;14:287-300.
39. Thomas S, Shah G. Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther 2005;4:1226-33.
40. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002;13:2276-88.
41. Maeno E, Ishizaki Y, Kanaseki T, Hazama A, Okada Y. Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proc Natl Acad Sci U S A 2000;97:9487-92.
42. Panayiotidis MI, Bortner CD, Cidlowski JA. On the mechanism of ionic regulation of apoptosis: would the Na +/K + -ATPase please stand up? Acta Physiol (Oxf) 2006;187:205-15.
43. Yurinskaya V, Goryachaya T, Guzhova I, et al. Potassium and sodium balance in U937 cells during apoptosis with and without cell shrinkage. Cell Physiol Biochem 2005;16:155-62.
44. Yurinskaya VE, Moshkov AV, Rozanov YM, et al. Thymocyte K+, Na+ and water balance during dexamethasone- and etoposide-induced apoptosis. Cell Physiol Biochem 2005;16:15-22.
45. Arrebola F, Zabiti S, Canizares FJ, Cubero MA, Crespo PV, Fernandez-Segura E. Changes in intracellular sodium, chlorine, and potassium concentrations in staurosporine-induced apoptosis. J Cell Physiol 2005; 204:500-7.
46. Albrecht M, Doroszewicz J, Gillen S, et al. Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1β with IL-1β acting as a modulator of cellular differentiation. Prostate 2004;58:82-94.
47. Xiao D, Chinnappan D, Pestell R, Albanese C, Weber HC. Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells. Cancer Res 2005;65:9934-42.